Skip to search formSkip to main contentSkip to account menu

AZD1775

Known as: AZD-1775, WEE1 Inhibitor AZD1775 
A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. AZD1775 selectively targets and inhibits… 
National Institutes of Health

Related topics

Related topics

3 relations
MK 1775NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib)
Background: Wee1 tyrosine kinase phosphorylates and inactivates cyclin dependent kinase (Cdk) 1 as part of DNA damage response… 
2019
2019
DNA Damage Repair Interference By WEE1 Inhibition with AZD1775 Overcomes Combined Azacitidine and Venetoclax Resistance in Acute Myeloid Leukmeia (AML)
Acute myeloid leukemia (AML) has remained one of the most treatment resistant and deadliest cancers. The survival of AML blast… 
2017
2017
Abstract CT144: Pediatric phase I trial of the WEE1 inhibitor AZD1775 and irinotecan in patients with refractory solid and CNS malignancies; A Children’s Oncology Group Study (ADVL1312)
Background: Inhibition of the WEE1 kinase by AZD1775 potentiates replicative stress induced by oncogenes or chemotherapy, and… 
2017
2017
Phase I study of definitive chemoradiation with gemcitabine and the WEE1 inhibitor AZD1775 in unresectable pancreatic cancer.
TPS512Background: Targeting cell cycle checkpoints has the potential to enhance the efficacy of chemoradiation therapy. Tumor… 
2017
2017
A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly cisplatin and docetaxel in borderline resectable head and neck squamous cell carcinoma (HNSCC).
6034Background: The WEE1 tyrosine kinase regulates G2/M transition and maintains genomic stability. In TP53-deficient tumors (via… 
Review
2017
Review
2017
Abstract CT004: European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study
In the area of precision medicine we initiated the multi-centric, international trials MAPPYACTS ‘A multicentric, prospective… 
2016
2016
A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.
5562Background: Tumors with G1/S checkpoint deficiencies rely on Wee1 kinase to arrest cell cycle progression at G2/M to repair… 
2016
2016
Phase ib trial of dose-escalating AZD1775 in combination with concurrent radiation and cisplatin for intermediate and high risk head and neck squamous cell carcinoma.
TPS6106Background: Patients with significant tobacco histories (intermediate risk) and those who are HPV negative (high risk… 
2016
2016
Abstract CT013: A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors…
Many cancers are associated with DNA repair and cell cycle mutations that result in G1/S checkpoint deficiencies and higher… 
2014
2014
Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors.
2503 Background: Wee1 tyrosine kinase phosphorylates and inactivates Cdk1, causing G2 cell cycle arrest in response to DNA damage… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)